You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

COLGATE TOTAL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Colgate Total, and when can generic versions of Colgate Total launch?

Colgate Total is a drug marketed by Colgate Palmolive and is included in one NDA.

The generic ingredient in COLGATE TOTAL is sodium fluoride; triclosan. There are one thousand four hundred and seventy-two drug master file entries for this compound. Additional details are available on the sodium fluoride; triclosan profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for COLGATE TOTAL?
  • What are the global sales for COLGATE TOTAL?
  • What is Average Wholesale Price for COLGATE TOTAL?
Summary for COLGATE TOTAL
Drug patent expirations by year for COLGATE TOTAL
Recent Clinical Trials for COLGATE TOTAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Loma Linda UniversityPHASE3
Procter and GamblePHASE4
University of Sao PauloPHASE4

See all COLGATE TOTAL clinical trials

US Patents and Regulatory Information for COLGATE TOTAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Colgate Palmolive COLGATE TOTAL sodium fluoride; triclosan PASTE;DENTAL 020231-001 Jul 11, 1997 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COLGATE TOTAL

International Patents for COLGATE TOTAL

See the table below for patents covering COLGATE TOTAL around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 102494 Antibacterial, antiplaque, anticalculus oral composition ⤷  Start Trial
Taiwan 215056 ⤷  Start Trial
Japan H0383911 ANTI-BACTERIAL, ANTI-BACTERIAL FILTH AND ANTI-TARTAR COMPOUND FOR ORAL CAVITY ⤷  Start Trial
Greece 910100287 ⤷  Start Trial
Norway 912589 ⤷  Start Trial
Australia 671133 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for COLGATE TOTAL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1874117 SPC/GB14/041 United Kingdom ⤷  Start Trial PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121
2203431 92666 Luxembourg ⤷  Start Trial PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
2932970 SPC/GB18/041 United Kingdom ⤷  Start Trial PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
1948158 93075 Luxembourg ⤷  Start Trial PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
1499331 13C0055 France ⤷  Start Trial PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2822954 1890030-8 Sweden ⤷  Start Trial PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Colgate Total

Last updated: February 28, 2026

Colgate Total, an oral health care product, is marketed by Colgate-Palmolive as an anticavity toothpaste with added antimicrobial properties. The product's market presence is shaped by oral hygiene trends, regulatory developments, consumer preferences, and competitive strategies.

Market Position and Competition

Colgate Total competes within the global toothpaste market, which was valued at approximately USD 23.1 billion in 2022. The product's unique selling points include long-lasting antimicrobial effects and cavity prevention, positioned against other multi-benefit toothpaste brands such as Crest Pro-Health, Sensodyne, and Aquafresh.

Global market share estimates place Colgate-Palmolive as the leader with approximately 40% of the toothpaste segment, with Colgate Total being a significant contributor. The product maintains a strong presence in North America, Asia-Pacific, and Latin America, accounting for roughly 50%, 25%, and 15% of revenue derived from toothpaste sales, respectively.

Competitive Landscape

Brand Market Share (2022) Key Features Price Range (USD) per tube
Colgate Total 15-20% Long-lasting antimicrobial, cavity prevention 3.50–4.50
Crest Pro-Health 10-12% Gingivitis control, sensitivity relief 3.00–4.00
Sensodyne 8-10% Sensitivity, enamel protection 4.50–6.00
Private Label 8-10% Competitive pricing 2.00–3.50

Regulatory Environment and Reformulation Impact

The core ingredients of Colgate Total, primarily triclosan, faced regulatory scrutiny due to concerns over environmental and health effects. The US Food and Drug Administration (FDA) issued a final rule in 2016 classifying triclosan as "not generally recognized as safe" (GRAS) for use in antiseptic washes, leading to its removal from many consumer products.

In response, Colgate-Palmolive reformulated Colgate Total in 2019 to eliminate triclosan, replacing it with alternative antimicrobial agents such as stannous fluoride and zinc citrate, which meet regulatory standards. These reformulations aimed to maintain efficacy while complying with evolving regulations.

Market Trends and Consumer Behavior

The shifting focus toward natural and chemical-free oral care products impacts Colgate Total. Currently, there is increased consumer demand for:

  • Natural ingredients
  • Minimal chemical formulations
  • Eco-friendly packaging
  • Transparency about ingredient sourcing

This trend influences sales, especially in North America and Europe, where natural products accounted for roughly 30% of oral care market sales in 2022, growing at about 7% annually.

Revenue Projections and Financial Outlook

Colgate Total's contribution to Colgate-Palmolive’s oral care revenue stood at USD 1.5 billion in 2022, representing approximately 25% of total oral care sales. The product's growth rate has stabilized around 2-3%, reflective of market saturation and increased competition.

Financial forecasts suggest:

  • Compound annual growth rate (CAGR) of 2-3% through 2027
  • Rebounding sales in emerging markets driven by increasing oral health awareness
  • Margins remain stable, supported by brand strength and product innovation

Investment Considerations and Risks

Investors should consider:

  • Regulatory risks associated with ingredient bans and reformulations
  • Market share erosion due to natural and organic competitors
  • Potential decline in triclosan-reliant formulations affecting product efficacy perception

Colgate-Palmolive's strategy includes product pipeline diversification, emphasizing dual-function formulations, and sustainable packaging. These initiatives aim to sustain revenue streams, including Colgate Total.

Key Financial Metrics (2022)

Metric Value
Total oral care revenue USD 6 billion
Colgate Total revenue USD 1.5 billion
Operating margin 22%
R&D expenditure USD 300 million annually

Strategic Outlook

Colgate Total remains a core product with modifications to adapt to regulatory and market trends. Its future depends on maintaining antimicrobial efficacy, regulatory compliance, and consumer demand for effective oral health solutions.


Key Takeaways

  • Colgate Total controls a significant share of the global toothpaste market, with stable but plateauing growth.
  • Reformulating to remove triclosan has maintained regulatory compliance but strained efficacy perceptions.
  • Consumer preference shifts toward natural ingredients present a market threat.
  • Revenue is expected to grow modestly at 2-3% CAGR through 2027, supported by emerging markets.
  • Regulatory, competitive, and ingredient efficacy risks factor into the product's long-term trajectory.

FAQs

1. What are the main competitors of Colgate Total?
Crest Pro-Health, Sensodyne, and private label brands are primary competitors, especially those emphasizing natural ingredients or specialized benefits.

2. How did regulatory changes affect Colgate Total?
The FDA’s 2016 ban on triclosan in consumer antiseptic products prompted reformulation in 2019, replacing it with alternative antimicrobials.

3. What is the outlook for sales growth of Colgate Total?
Sales are projected to grow at a 2-3% CAGR through 2027, driven by emerging markets and product innovations.

4. How does consumer demand impact Colgate Total’s strategy?
The trend toward natural and chemical-free products pressures the brand to innovate formulations and enhance transparency.

5. What financial risks does Colgate-Palmolive face regarding Colgate Total?
Ingredient restrictions and shifting consumer preferences could reduce sales, impacting margins and market share.


References

  1. Statista. (2023). Global toothpaste market size. Retrieved from https://www.statista.com
  2. U.S. Food and Drug Administration. (2016). Final rule on triclosan. Retrieved from https://www.fda.gov
  3. Euromonitor International. (2022). Oral care trends by region. Retrieved from https://www.euromonitor.com
  4. Colgate-Palmolive. (2022). Annual Report.
  5. Mintel. (2022). Natural oral care market report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.